TABLE 4.
A comparison of pharmacokinetic parameters of 17-OHPC in singleton and twin gestation
| Variable | AUCt1t2 (ng/mL/d) | Ctrough (ng/mL) | CMAX (ng/mL) | TMAX (d) |
| Singleton gestation (n = 47) | 115.2 ± 44.2 (78.8–141.4) | 14.1 ± 5.6 (10–18.1) | 22.6 ± 9.5 (15.8–27.4) | 2.1 ± 1.9 (1.0–3.0) |
| Twin gestation (n = 6) | 86.0 ± 33.5 (61.0–114.0) | 9.7 ± 2.8 (8.0–12.0) | 17 ± 6.7 (12.0–22.0) | 1.2 ± 0.4 (1.0–2.0) |
| P value | .06 | .05 | .12 | .36 |
Data are given as mean pharmacokinetic parameters ± SD (interquartile range; Q1–Q3, where Q1 is the 25th percentile and Q3 is the 75th percentile) that were observed for 47 subjects with singleton gestation and 6 subjects with twin gestation who had sampling done daily for 7 days after an injection and received all scheduled injections. Wilcoxon signed rank test used to compare pharmacokinetic parameters between groups.
AUCt1t2, area under the concentration vs time curve; CMAX, maximum concentration during the dosing interval; Ctrough, the minimum concentration just before the next dose; 17-OHPC, 17-hydroxyprogesterone caproate; TMAX, time to maximum concentration.
Caritis. Pharmacology and placental transport of 17-OHPC. Am J Obstet Gynecol 2012.